Search

Displaying results 2411 - 2420 of 4599 in total
  1. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression

  2. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Casimersen is currently marketed under the tradename AMONDYS 45™ by Sarepta Therapeutics, Inc.[L32118] … However, the specific mutations, and hence the precise exon skipping, targeted by each is different.

  3. Drug

    Estradiol

    go.drugbank.com/drugs/DB00783
    ApprovedInvestigationalVet approved

    Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and h...

  4. Drug

    Doravirine

    go.drugbank.com/drugs/DB12301
    ApprovedInvestigational

    [L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).

  5. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.

  6. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

  7. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

  8. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

  9. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

  10. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.